| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Endocrinology, Vol 9, 794-804, Copyright © 1995 by Endocrine Society
ARTICLES |
H Keller, F Givel, M Perroud and W Wahli
Institut de Biologie animale, Universite de Lausanne, Switzerland.
Peroxisome proliferator-activated receptors (PPARs) and retinoid X receptors (RXRs) are nuclear hormone receptors that are activated by fatty acids and 9-cis-retinoic acid, respectively. PPARs and RXRs form heterodimers that activate transcription by binding to PPAR response elements (PPREs) in the promoter of target genes. The PPREs described thus far consist of a direct tandem repeat of the AGGTCA core element with one intervening nucleotide. We show here that the vitellogenin A2 estrogen response element (ERE) can also function as a PPRE and is bound by a PPAR/RXR heterodimer. Although this heterodimer can bind to several other ERE-related palindromic response elements containing AGGTCA half-sites, only the ERE is able to confer transactivation of test reporter plasmids, when the ERE is placed either close to or at a distance from the transcription initiation site. Examination of natural ERE-containing promoters, including the pS2, very-low-density apolipoprotein II and vitellogenin A2 genes, revealed considerable differences in the binding of PPAR/RXR heterodimers to these EREs. In their natural promoter context, these EREs did not allow transcriptional activation by PPARs/RXRs. Analysis of this lack of stimulation of the vitellogenin A2 promoter demonstrated that PPARs/RXRs bind to the ERE but cannot transactivate due to a nonpermissive promoter structure. As a consequence, PPARs/RXRs inhibit transactivation by the estrogen receptor through competition for ERE binding. This is the first example of signaling cross-talk between PPAR/RXR and estrogen receptor.
This article has been cited by other articles:
 |
|
 |
|
  L. D. Yee, N. Williams, P. Wen, D. C. Young, J. Lester, M. V. Johnson, W. B. Farrar, M. J. Walker, S. P. Povoski, S. Suster, et al. Pilot Study of Rosiglitazone Therapy in Women with Breast Cancer: Effects of Short-term Therapy on Tumor Tissue and Serum Markers Clin. Cancer Res., January 1, 2007; 13(1): 246 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Suzuki, S Hayashi, Y Miki, Y Nakamura, T Moriya, A Sugawara, T Ishida, N Ohuchi, and H Sasano Peroxisome proliferator-activated receptor {gamma} in human breast carcinoma: a modulator of estrogenic actions. Endocr. Relat. Cancer, March 1, 2006; 13(1): 233 - 250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Dyroy, A. Yndestad, T. Ueland, B. Halvorsen, J. K. Damas, P. Aukrust, and R. K. Berge Antiinflammatory Effects of Tetradecylthioacetic Acid Involve Both Peroxisome Proliferator-Activated Receptor {alpha}-Dependent and -Independent Pathways Arterioscler. Thromb. Vasc. Biol., July 1, 2005; 25(7): 1364 - 1369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Y. Honisett, L. Stojanovska, K. Sudhir, B. A. Kingwell, T. Dawood, and P. A. Komesaroff Hormone Therapy Impairs Endothelial Function in Postmenopausal Women with Type 2 Diabetes Mellitus Treated with Rosiglitazone J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4615 - 4619. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Stephen, M. C. U. Gustafsson, M. Jarvis, R. Tatoud, B. R. Marshall, D. Knight, E. Ehrenborg, A. L. Harris, C. R. Wolf, and C. N. A. Palmer Activation of Peroxisome Proliferator-Activated Receptor {delta} Stimulates the Proliferation of Human Breast and Prostate Cancer Cell Lines Cancer Res., May 1, 2004; 64(9): 3162 - 3170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Tanmahasamut, J. Liu, L. B. Hendry, and N. Sidell Conjugated Linoleic Acid Blocks Estrogen Signaling in Human Breast Cancer Cells J. Nutr., March 1, 2004; 134(3): 674 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Wang, X. Y. Yang, X. Zhang, K. Mihalic, W. Xiao, and W. L. Farrar The cis Decoy against the Estrogen Response Element Suppresses Breast Cancer Cells via Target Disrupting c-fos not Mitogen-activated Protein Kinase Activity Cancer Res., May 1, 2003; 63(9): 2046 - 2051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. Houston, J. A. Copland, R. R. Broaddus, M. M. Gottardis, S. M. Fischer, and C. L. Walker Inhibition of Proliferation and Estrogen Receptor Signaling by Peroxisome Proliferator-activated Receptor {gamma} Ligands in Uterine Leiomyoma Cancer Res., March 15, 2003; 63(6): 1221 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dowdy, S. Brower, and M. R. Miller Acetaminophen Exhibits Weak Antiestrogenic Activity in Human Endometrial Adenocarcinoma (Ishikawa) Cells Toxicol. Sci., March 1, 2003; 72(1): 57 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rieusset, F. Touri, L. Michalik, P. Escher, B. Desvergne, E. Niesor, and W. Wahli A New Selective Peroxisome Proliferator-Activated Receptor {gamma} Antagonist with Antiobesity and Antidiabetic Activity Mol. Endocrinol., November 1, 2002; 16(11): 2628 - 2644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Min, H. Kim, Y. Bae, L. Petz, and J. K. Kemper Inhibitory Cross-talk between Estrogen Receptor (ER) and Constitutively Activated Androstane Receptor (CAR). CAR INHIBITS ER-MEDIATED SIGNALING PATHWAY BY SQUELCHING p160 COACTIVATORS J. Biol. Chem., September 6, 2002; 277(37): 34626 - 34633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Yamakawa-Kobayashi, H Ishiguro, T Arinami, R Miyazaki, and H Hamaguchi A Val227Ala polymorphism in the peroxisome proliferator activated receptor {alpha} (PPAR{alpha}) gene is associated with variations in serum lipid levels J. Med. Genet., March 1, 2002; 39(3): 189 - 191. [Full Text]
|
|
|
|
 |
|
 D. Linden, M. Alsterholm, H. Wennbo, and J. Oscarsson PPAR{alpha} deficiency increases secretion and serum levels of apolipoprotein B-containing lipoproteins J. Lipid Res., November 1, 2001; 42(11): 1831 - 1840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Komar, O. Braissant, W. Wahli, and T. E. Curry Jr. Expression and Localization of PPARs in the Rat Ovary During Follicular Development and the Periovulatory Period Endocrinology, November 1, 2001; 142(11): 4831 - 4838. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Parlesak, I Menzl, A Feuchter, J C Bode, and C Bode Inhibition of retinol oxidation by ethanol in the rat liver and colon Gut, December 1, 2000; 47(6): 825 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Y. Osamura, S. Tahara, R. Kurotani, N. Sanno, A. Matsuno, and A. Teramoto Contributions of Immunohistochemistry and In Situ Hybridization to the Functional Analysis of Pituitary Adenomas J. Histochem. Cytochem., April 1, 2000; 48(4): 445 - 458. [Abstract] [Full Text]
|
|
|
|
|
|
J. C. M. Tsibris, K. B. Porter, A. Jazayeri, G. Tzimas, H. Nau, H. Huang, K. Kuparadze, G. W. Porter, W. F. O'Brien, and W. N. Spellacy Human Uterine Leiomyomata Express Higher Levels of Peroxisome Proliferator-activated Receptor {{gamma}}, Retinoid X Receptor {{alpha}}, and all-trans Retinoic Acid Than Myometrium Cancer Res., November 1, 1999; 59(22): 5737 - 5744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Desvergne and W. Wahli Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism Endocr. Rev., October 1, 1999; 20(5): 649 - 688. [Abstract] [Full Text]
|
|
|
|
|
|
H. Ma, H. W. Sprecher, and P. E. Kolattukudy Estrogen-induced Production of a Peroxisome Proliferator-activated Receptor (PPAR) Ligand in a PPARgamma -expressing Tissue J. Biol. Chem., November 13, 1998; 273(46): 30131 - 30138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Tolon, A. I. Castillo, and A. Aranda Activation of the Prolactin Gene by Peroxisome Proliferator-activated Receptor-alpha Appears to Be DNA Binding-independent J. Biol. Chem., October 9, 1998; 273(41): 26652 - 26661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Ren, A. P. Thelen, J. M. Peters, F. J. Gonzalez, and D. B. Jump Polyunsaturated Fatty Acid Suppression of Hepatic Fatty Acid Synthase and S14 Gene Expression Does Not Require Peroxisome Proliferator-activated Receptor alpha J. Biol. Chem., October 24, 1997; 272(43): 26827 - 26832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Arts, M. Kockx, H. M.G. Princen, and T. Kooistra Studies on the Mechanism of Fibrate-Inhibited Expression of Plasminogen Activator Inhibitor-1 in Cultured Hepatocytes From Cynomolgus Monkey Arterioscler. Thromb. Vasc. Biol., January 1, 1997; 17(1): 26 - 32. [Abstract] [Full Text]
|
|
|
|
 |
|
 X. Ma, D. A. Stoffregen, G. D. Wheelock, J. A. Rininger, and J. G. Babish Discordant Hepatic Expression of the Cell Division Control Enzyme p34cdc2 Kinase, Proliferating Cell Nuclear Antigen, p53 Tumor Suppressor Protein, and p21Waf1 Cyclin-Dependent Kinase Inhibitory Protein after WY14,643 ([4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio]Acetic Acid) Dosing to Rats Mol. Pharmacol., January 1, 1997; 51(1): 69 - 78. [Abstract] [Full Text]
|
|
|
|
|
|
B. Ren, A. Thelen, and D. B. Jump Peroxisome Proliferator-activated Receptor alpha Inhibits Hepatic S14 Gene Transcription. EVIDENCE AGAINST THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR alpha AS THE MEDIATOR OF POLYUNSATURATED FATTY ACID REGULATION OF S14 GENE TRANSCRIPTION J. Biol. Chem., July 19, 1996; 271(29): 17167 - 17173. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
